| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1005375681 |
| P356 | DOI | 10.1007/S11910-014-0499-8 |
| P932 | PMC publication ID | 4162987 |
| P698 | PubMed publication ID | 25217249 |
| P5875 | ResearchGate publication ID | 265608377 |
| P50 | author | Colin L. Masters | Q1108510 |
| Neill R Graff-Radford | Q91360658 | ||
| Alison Goate | Q45660395 | ||
| Bernardino F. Ghetti | Q56863342 | ||
| P2093 | author name string | John C. Morris | |
| Adrian Danek | |||
| Nigel J. Cairns | |||
| John M. Ringman | |||
| P2860 | cites work | The effect of APOE genotype on clinical phenotype in Alzheimer disease | Q57384568 |
| Amyloid beta protein precursor gene and hereditary cerebral hemorrhage with amyloidosis (Dutch) | Q57849311 | ||
| Alzheimer's disease | Q69879466 | ||
| Role of Genes and Environments for Explaining Alzheimer Disease | Q22253029 | ||
| Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer's disease | Q24312938 | ||
| Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease | Q24316501 | ||
| ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models | Q24628845 | ||
| The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics | Q27860914 | ||
| Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium | Q28252389 | ||
| APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy | Q28288090 | ||
| Alzheimer's disease and endocytic dysfunction: clues from the Down syndrome-related proteins, DSCR1 and ITSN1 | Q28294319 | ||
| Candidate gene for the chromosome 1 familial Alzheimer's disease locus | Q28295424 | ||
| Alzheimer's presenilin 1 mutations impair kinesin-based axonal transport | Q28512320 | ||
| Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network | Q28714253 | ||
| Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia | Q29397661 | ||
| Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein | Q29547803 | ||
| Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease | Q29614374 | ||
| Decreased clearance of CNS beta-amyloid in Alzheimer's disease | Q29616534 | ||
| The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor | Q29618322 | ||
| Clinical and biomarker changes in dominantly inherited Alzheimer's disease | Q29619940 | ||
| Brain differences in infants at differential genetic risk for late-onset Alzheimer disease: a cross-sectional imaging study | Q30435790 | ||
| Increased in vivo amyloid-β42 production, exchange, and loss in presenilin mutation carriers | Q30557695 | ||
| Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial. | Q30561855 | ||
| What the study of persons at risk for familial Alzheimer's disease can tell us about the earliest stages of the disorder: a review | Q31020589 | ||
| Synthesis, aggregation, neurotoxicity, and secondary structure of various A beta 1-42 mutants of familial Alzheimer's disease at positions 21-23. | Q31072457 | ||
| Epilepsy and cognitive impairments in Alzheimer disease | Q33616746 | ||
| Distinct cerebrospinal fluid amyloid beta peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer's disease | Q33638748 | ||
| 18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons | Q33740879 | ||
| Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis | Q33777535 | ||
| What the evolution of the amyloid protein precursor supergene family tells us about its function | Q33838961 | ||
| Clinical predictors of severe cerebral amyloid angiopathy and influence of APOE genotype in persons with pathologically verified Alzheimer disease | Q33911295 | ||
| Relationship between severe amyloid angiopathy, apolipoprotein E genotype, and vascular lesions in Alzheimer's disease | Q33922691 | ||
| Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels | Q33931836 | ||
| Autosomal-dominant Alzheimer's disease mutations at the same codon of amyloid precursor protein differentially alter Aβ production | Q39080810 | ||
| Regulated intramembrane proteolysis of amyloid precursor protein and regulation of expression of putative target genes | Q40275063 | ||
| Presenilin regulates capacitative calcium entry dependently and independently of gamma-secretase activity. | Q40521056 | ||
| Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging | Q43062420 | ||
| High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types | Q43222788 | ||
| The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's syndrome | Q43835260 | ||
| Ectopic white matter neurons, a developmental abnormality that may be caused by the PSEN1 S169L mutation in a case of familial AD with myoclonus and seizures | Q43838097 | ||
| Two novel presenilin-1 mutations (Y256S and Q222H) are associated with early-onset Alzheimer's disease. | Q44529071 | ||
| The apolipoprotein E epsilon 4 allele is associated with increased neuritic plaques and cerebral amyloid angiopathy in Alzheimer's disease and Lewy body variant | Q46323718 | ||
| The impact of different presenilin 1 andpresenilin 2 mutations on amyloid deposition, neurofibrillary changes and neuronal loss in the familial Alzheimer's disease brain: evidence for other phenotype-modifying factors | Q48123629 | ||
| Insensitivity to Abeta42-lowering nonsteroidal anti-inflammatory drugs and gamma-secretase inhibitors is common among aggressive presenilin-1 mutations | Q48134209 | ||
| Differential effect of APOE genotype on amyloid load and glucose metabolism in AD dementia | Q48246691 | ||
| Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type | Q48265529 | ||
| Molecular mapping of Alzheimer-type dementia in Down's syndrome | Q48512105 | ||
| Endocytic disturbances distinguish among subtypes of Alzheimer's disease and related disorders | Q48712994 | ||
| TDP-43 pathological changes in early onset familial and sporadic Alzheimer's disease, late onset Alzheimer's disease and Down's syndrome: association with age, hippocampal sclerosis and clinical phenotype | Q48864196 | ||
| An English translation of Alzheimer's 1907 paper, "Uber eine eigenartige Erkankung der Hirnrinde". | Q48903618 | ||
| The E280A presenilin 1 Alzheimer mutation produces increased A beta 42 deposition and severe cerebellar pathology | Q48911162 | ||
| Amyloid beta protein (Abeta) deposition in chromosome 14-linked Alzheimer's disease: predominance of Abeta42(43). | Q48956388 | ||
| A novel mutation in the PSEN1 gene (L286P) associated with familial early-onset dementia of Alzheimer type and lobar haematomas. | Q51969545 | ||
| Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the beta-amyloid precursor protein gene. | Q53178823 | ||
| Amyloid A4 protein and its precursor in Down's syndrome and Alzheimer's disease. | Q53187594 | ||
| Genetic linkage studies suggest that Alzheimer's disease is not a single homogeneous disorder. | Q53299482 | ||
| The exception makes the rule: not all Aβ plaques are created equal. | Q53329554 | ||
| Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers. | Q53329558 | ||
| Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments | Q34039983 | ||
| Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo | Q34063772 | ||
| Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease | Q34157492 | ||
| Notch and Presenilin: regulated intramembrane proteolysis links development and degeneration. | Q34194714 | ||
| Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production | Q34280406 | ||
| Down's syndrome and Alzheimer's disease: towards secondary prevention | Q34296806 | ||
| SUCLG2 identified as both a determinator of CSF Aβ1-42 levels and an attenuator of cognitive decline in Alzheimer's disease | Q34429207 | ||
| The role of apolipoprotein E in Alzheimer's disease | Q34603092 | ||
| A familial Alzheimer's disease locus on chromosome 1. | Q34720942 | ||
| Hippocampal sclerosis in advanced age: clinical and pathological features. | Q34992164 | ||
| Amyloid mediates the association of apolipoprotein E e4 allele to cognitive function in older people | Q35490069 | ||
| Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees | Q35694218 | ||
| Comparison of clinical characteristics between familial and non-familial early onset Alzheimer's disease | Q36233510 | ||
| Familial Alzheimer's disease mutations differentially alter amyloid β-protein oligomerization | Q36415249 | ||
| Oxidative stress: a bridge between Down's syndrome and Alzheimer's disease | Q36453571 | ||
| Distinct patterns of APP processing in the CNS in autosomal-dominant and sporadic Alzheimer disease | Q36756941 | ||
| Plasma signaling proteins in persons at genetic risk for Alzheimer disease: influence of APOE genotype | Q36888445 | ||
| Cerebral amyloid angiopathy: pathogenetic mechanisms and link to dense amyloid plaques. | Q37053953 | ||
| Mosaicism for trisomy 21 in a patient with young-onset dementia: a case report and brief literature review | Q37106886 | ||
| Association of plasma and cortical amyloid beta is modulated by APOE ε4 status | Q37112462 | ||
| Down's syndrome, neuroinflammation, and Alzheimer neuropathogenesis | Q37113208 | ||
| Genetic influences on atrophy patterns in familial Alzheimer's disease: a comparison of APP and PSEN1 mutations | Q37170650 | ||
| Subjects harboring presenilin familial Alzheimer's disease mutations exhibit diverse white matter biochemistry alterations | Q37199229 | ||
| Clinical and neuropathological features of the arctic APP gene mutation causing early-onset Alzheimer disease | Q37297066 | ||
| Early onset familial Alzheimer Disease with spastic paraparesis, dysarthria, and seizures and N135S mutation in PSEN1. | Q37361233 | ||
| Neuritic plaques and cerebrovascular amyloid in Alzheimer disease are antigenically related | Q37558902 | ||
| New genes and new insights from old genes: update on Alzheimer disease | Q37560444 | ||
| APOE ε4 worsens hippocampal CA1 apical neuropil atrophy and episodic memory | Q37623222 | ||
| Greater medial temporal hypometabolism and lower cortical amyloid burden in ApoE4-positive AD patients | Q37624214 | ||
| Regional distribution of synaptic markers and APP correlate with distinct clinicopathological features in sporadic and familial Alzheimer's disease | Q37723422 | ||
| The amyloid precursor protein: a biochemical enigma in brain development, function and disease | Q38107684 | ||
| Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis | Q38220107 | ||
| Apolipoprotein E epsilon4 allele, AD pathology, and the clinical expression of Alzheimer's disease | Q38430226 | ||
| Recent Perspectives on APP, Secretases, Endosomal Pathways and How they Influence Alzheimer's Related Pathological Changes in Down Syndrome | Q38982671 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | genetic variation | Q349856 |
| membrane protein | Q423042 | ||
| genetic heterogeneity | Q3733697 | ||
| Alzheimer's disease | Q11081 | ||
| P304 | page(s) | 499 | |
| P577 | publication date | 2014-11-01 | |
| P1433 | published in | Current Neurology and Neuroscience Reports | Q18206211 |
| P1476 | title | Genetic heterogeneity in Alzheimer disease and implications for treatment strategies | |
| P478 | volume | 14 |
| Q26770781 | Chronic Glutamate Toxicity in Neurodegenerative Diseases-What is the Evidence? |
| Q36615510 | Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer's disease |
| Q38654257 | Identification of clusters of rapid and slow decliners among subjects at risk for Alzheimer's disease |
| Q50421378 | Impairment of memory generalization in preclinical autosomal dominant Alzheimer's disease mutation carriers. |
| Q37069525 | Neuropathology of Autosomal Dominant Alzheimer Disease in the National Alzheimer Coordinating Center Database. |
| Q39277398 | Neurovascular Alterations in Alzheimer's Disease: Transporter Expression Profiles and CNS Drug Access |
| Q38796814 | New Genetic Approaches to AD: Lessons from APOE-TOMM40 Phylogenetics |
| Q38802995 | Proteomics as an innovative tool to investigate frontotemporal disorders |
| Q55178076 | Reduced penetrance of the PSEN1 H163Y autosomal dominant Alzheimer mutation: a 22-year follow-up study. |
| Q64073926 | Reverse GWAS: Using genetics to identify and model phenotypic subtypes |
| Q38610500 | Sleep, Cognition and Dementia |
| Q39339952 | Targeting Neural Hyperactivity as a Treatment to Stem Progression of Late-Onset Alzheimer's Disease |
| Q52620416 | The genes associated with early-onset Alzheimer's disease. |
| Q27005952 | The promise of multi-omics and clinical data integration to identify and target personalized healthcare approaches in autism spectrum disorders |
| Q33838470 | Therapeutic Applications of Rose Hips from Different Rosa Species. |
| Q64236125 | Treatment Combinations for Alzheimer's Disease: Current and Future Pharmacotherapy Options |
| Q92416317 | WITHDRAWN: Mental Disorders in Young Adults from Families with the Presenilin-1 Gene Mutation E280A in the Preclinical Stage of Alzheimer's Disease |
Search more.